Off-Label Drug Proves Its Mettle in Relapsing Multiple Sclerosis

(MedPage Today) — Off-label rituximab was noninferior to ocrelizumab (Ocrevus) in people with newly diagnosed relapsing multiple sclerosis (MS) and recent disease activity, the phase III OVERLORD-MS trial showed.
At 2 years, the estimated probability…

Source link : https://www.medpagetoday.com/neurology/multiplesclerosis/122021

Author :

Publish date : 2026-07-01 21:26:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Off-Label Drug Proves Its Mettle in Relapsing Multiple Sclerosis

FDA Scientists Raise Peptide Concerns Ahead of Committee Meeting

Amnioinfusions Mitigate Lethal Lung Hypoplasia From Fetal Kidney Failure

Related Posts

Amnioinfusions Mitigate Lethal Lung Hypoplasia From Fetal Kidney Failure

FDA Scientists Raise Peptide Concerns Ahead of Committee Meeting

Diet Still Matters After Alzheimer’s Pathology Occurs

Psychiatric Risk Transmission; Phase III Win, Flop for Anxiety; 10K Hotel Overdoses

Emails Reveal How RFK Jr. Empowered a Lone CDC Scientist

Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers

Amnioinfusions Mitigate Lethal Lung Hypoplasia From Fetal Kidney Failure

Off-Label Drug Proves Its Mettle in Relapsing Multiple Sclerosis

FDA Scientists Raise Peptide Concerns Ahead of Committee Meeting

Diet Still Matters After Alzheimer’s Pathology Occurs

Psychiatric Risk Transmission; Phase III Win, Flop for Anxiety; 10K Hotel Overdoses

Emails Reveal How RFK Jr. Empowered a Lone CDC Scientist

Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers

Where the World Cup, Homelessness, and the ED Meet

Categories

Archives